• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Liquidia Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    6/8/26 4:30:38 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LQDA alert in real time by email
    false 0001819576 0001819576 2026-06-08 2026-06-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 8, 2026

     

    LIQUIDIA CORPORATION
    (Exact name of registrant as specified in its charter)
         
    Delaware 001-39724 85-1710962
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)

     

    419 Davis Drive, Suite 100, Morrisville, North Carolina 27560
    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (919) 328-4400 

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common stock LQDA The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 8.01 Other Events.

     

    On June 8, 2026, Liquidia Corporation, a Delaware corporation, issued a press release announcing that it will be added to the S&P SmallCap 600® Index, effective prior to the opening of trading on June 22, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d)

     

    Exhibit
    No.
      Exhibit
    99.1   Press Release of Liquidia Corporation, dated June 8, 2026.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    June 8, 2026 Liquidia Corporation
       
      By: /s/ Michael Kaseta
        Name: Michael Kaseta
        Title: Chief Financial Officer and Chief Operating Officer

     

     

     

    Get the next $LQDA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LQDA

    DatePrice TargetRatingAnalyst
    10/20/2025$31.00Overweight
    Wells Fargo
    8/15/2025$43.00Buy
    Jefferies
    5/19/2025$13.00Perform → Underperform
    Oppenheimer
    12/20/2024$20.00Overweight
    Wells Fargo
    10/16/2024Sector Outperform
    Scotiabank
    8/19/2024Outperform → Strong Buy
    Raymond James
    8/16/2024$27.00Outperform
    Raymond James
    6/25/2024Perform
    Oppenheimer
    More analyst ratings

    $LQDA
    SEC Filings

    View All

    Liquidia Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Liquidia Corp (0001819576) (Filer)

    6/8/26 4:30:38 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Liquidia Corporation

    144 - Liquidia Corp (0001819576) (Subject)

    6/8/26 4:11:06 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Liquidia Corporation

    144 - Liquidia Corp (0001819576) (Subject)

    6/4/26 6:38:03 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Tentative Approval for YUTREPIA issued to Liquidia Technologies, Inc.

    Submission status for Liquidia Technologies, Inc.'s drug YUTREPIA (ORIG-1) with active ingredient TREPROSTINIL has changed to 'Tentative Approval' on 11/04/2021. Application Category: NDA, Application Number: 213005, Application Classification: Type 3 - New Dosage Form

    11/18/21 2:49:33 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index

    MORRISVILLE, N.C., June 08, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will be added to the S&P SmallCap 600® Index, effective prior to the opening of trading on June 22, 2026. Introduced in 1994, the S&P SmallCap 600 is a widely followed benchmark of 600 U.S. small-cap companies selected by S&P Dow Jones Indices based on market capitalization, liquidity, shares available for public trading, and profitability criteria. Dr. Roger Jeffs, Liquidia's Chief Executive Officer, said: "Inclusion in the S&P Sm

    6/8/26 8:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, June 5, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 22, 2026, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from S&P MidCap 400 and S&P SmallCap 600 are no longer representative of the mid-cap and small-cap market space, respectively.  Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective DateIndex Name       ActionCompany NameTickerGICS SectorJune 22, 2026

    6/5/26 7:25:00 PM ET
    $BLKB
    $BRBR
    $CABO
    Computer Software: Prepackaged Software
    Technology
    Packaged Foods
    Consumer Staples

    Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference

    MORRISVILLE, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an update on the company's business in a fireside chat at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026, at 12:45 p.m. ET. Access to this event will be available on the "Investors" page of Liquidia's website at https://liquidia.com/investors/events-and-presentations. A replay of the webcast will be archived on the company's website for at least 30 days. About Liquidia Corporation Liquidia Corporation is a biopharmaceuti

    5/27/26 8:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Caligan Partners Lp bought $317,894 worth of shares (5,300 units at $59.98) and sold $317,894 worth of shares (5,300 units at $59.98) (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    5/20/26 8:51:06 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Manning Paul B bought $2,999,994 worth of shares (337,078 units at $8.90) (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    9/16/24 4:05:20 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Caligan Partners Lp disposed of 3,440,948 shares, sold $1,426,500 worth of shares (150,000 units at $9.51) and bought $1,426,500 worth of shares (150,000 units at $9.51) (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    9/4/24 5:51:34 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Liquidia Technologies with a new price target

    Wells Fargo initiated coverage of Liquidia Technologies with a rating of Overweight and set a new price target of $31.00

    10/20/25 8:01:49 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Liquidia Technologies with a new price target

    Jefferies resumed coverage of Liquidia Technologies with a rating of Buy and set a new price target of $43.00

    8/15/25 7:59:34 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Technologies downgraded by Oppenheimer with a new price target

    Oppenheimer downgraded Liquidia Technologies from Perform to Underperform and set a new price target of $13.00

    5/19/25 8:49:50 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manning Paul B sold $12,782,059 worth of shares (200,000 units at $63.91) (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    6/8/26 4:41:08 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bloch Stephen M sold $5,507,782 worth of shares (84,800 units at $64.95) (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    6/8/26 4:30:16 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Human Resource Officer Krepp Sarah sold $16,800 worth of shares (276 units at $60.87) as part of a pre-agreed trading plan, decreasing direct ownership by 0.19% to 146,743 units (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    6/3/26 4:31:20 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Leadership Updates

    Live Leadership Updates

    View All

    Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, June 5, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 22, 2026, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from S&P MidCap 400 and S&P SmallCap 600 are no longer representative of the mid-cap and small-cap market space, respectively.  Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective DateIndex Name       ActionCompany NameTickerGICS SectorJune 22, 2026

    6/5/26 7:25:00 PM ET
    $BLKB
    $BRBR
    $CABO
    Computer Software: Prepackaged Software
    Technology
    Packaged Foods
    Consumer Staples

    Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

    BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

    2/24/25 7:00:00 AM ET
    $AVIR
    $LQDA
    $KDMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

    GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent's 2024 Annual Meeting of Stockholders. Both joined as independent directors and bring more than 70 years of combined biopharmaceutical industry and sales experience. "Neal and Don bring unique and extensive expertise to Emergent as the company defines its future in this post-pandemic environment," said Emergent Chairman Dr. Zsolt Harsanyi, Ph.D. "Maintaining our focus on our mission of protecting and enhancing life, these industry veterans add v

    10/2/23 7:00:00 AM ET
    $EBS
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Liquidia Corporation

    SC 13G/A - Liquidia Corp (0001819576) (Subject)

    11/12/24 5:35:19 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Liquidia Corporation

    SC 13D/A - Liquidia Corp (0001819576) (Subject)

    9/12/24 4:22:57 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Liquidia Corporation

    SC 13D/A - Liquidia Corp (0001819576) (Subject)

    9/4/24 5:51:42 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Financials

    Live finance-specific insights

    View All

    Liquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026

    MORRISVILLE, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its first quarter 2026 financial results on Monday, May 11, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidi

    5/4/26 8:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Recorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continuesAchieved profitability in the first full quarter of YUTREPIA salesMore than 2,000 unique patient prescriptions and 1,500 patient starts to dateCompany to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced its financial results for the third quarter ended September 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern Time on November 3, 2025, to review financ

    11/3/25 6:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025

    MORRISVILLE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corporation is a b

    10/27/25 8:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care